LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid® technology for an undisclosed indication.
"I am pleased that we have signed this exciting collaboration," said Monica Wallter, CEO of LIDDS. "LIDDS favorable and clinically validated results using the NanoZolid® platform with different types of pharmaceutical substances, forms a bedrock for new and innovative oncology products."
The flexibility of the NanoZolid® technology offers a possibility to develop controlled and sustained release of many different drugs for local application in cancer tumors which improves its efficacy and provides fewer injections and less side effects for the patients.
For more information, please contact:
Monica Wallter, CEO, +46 (0)737 07 09 22, e-mail: monica.wallter@liddspharma.com
This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above on March 2, 2021 at 14:50 CET.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid is superior to any drug delivery technology in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North (LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Netbet Enterprises Limited27.3.2024 12:10:43 CET | Press release
NetBet Casino joins forces with Playson
Netbet Enterprises Limited27.3.2024 12:10:42 CET | Pressemeddelelse
NetBet Casino slår sig sammen med Playson
Cellebrite DI Ltd25.3.2024 12:01:12 CET | Press release
Cellebrite Hires Marketing Veteran David Gee as Chief Marketing Officer, Ushering in Next Phase of Growth, Scale and Market Leadership
Netbet Enterprises Limited22.3.2024 12:24:07 CET | Press release
NetBet Casino joins forces with Light & Wonder
Netbet Enterprises Limited22.3.2024 12:24:06 CET | Pressemeddelelse
NetBet Casino slår sig sammen med Light & Wonder
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom